Retatrutide (LY3437943) is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) studied for obesity and metabolic outcomes
This involves disturbances in glucose and fatty acid metabolism, as well as abnormalities in myocardial structure and function
Katie, Senior Manager of Scientific Affairs at Kyowa Hakko, discusses the latest studies on Setria, including new research on the Setria + citrulline combination for athletic performance and emerging data on immune and metabolic health applications
Both are backed by decades of research
While oral NAD+ supplements are widely available, many patients and providers prefer injectable formulations due to their enhanced bioavailability and more consistent results
Use consistently as part of your fitness and nutrition program for best results